130803-94-0

Basic information

• Product Name: 4-ethyl cyclohexane-1,3-dione
• CAS NO: 130803-94-0
• Molecular Weight: 140.182
• Mol File: 130803-94-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-ethyl cyclohexane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethyl cyclohexane-1,3-dione(130803-94-0)
• EPA Substance Registry System: 4-ethyl cyclohexane-1,3-dione(130803-94-0)

Safety Data

• Hazardous Substances Data: 130803-94-0(Hazardous Substances Data)

Upstream product

• 107-87-9 2-Pentanone 
• 140-88-5 ethyl acrylate 
• 69948-55-6 3-(2,2-dimethylhydrazino)cyclohex-2-en-1-one 
• 124015-81-2 3-(N',N'-Dimethyl-hydrazino)-4-ethyl-cyclohex-2-enone 
• 2896-60-8 4-ethyl-1,3-benzenediol 

Downstream Products

• 40397-69-1 3-Ethyl-2-hydroxy-6-oxo-cyclohex-1-enecarboxylic acid (4-chloro-2-methyl-phenyl)-amide 
• 40397-68-0 4'-chloro-3-ethyl-2-hydroxy-6-oxo-1-cyclohexene-1-carboxanilide 

Relevant articles and documents

Consecutive Michael-claisen process for cyclohexane-1,3-dione derivative (CDD) synthesis from unsubstituted and substituted acetone 1

A long-existing problem of cyclohexane-1,3-dione derivatives (CDD) synthesis from unreactive acetone through consecutive Michael-Claisen process was solved under this study. The practical applicability of this process was tested for a novel compound ethyl 3-(2,4-dioxocyclohexyl)propanoate for up to 20-gram scale. Furthermore, the scope of different acetone derivatives was investigated and resulted with similar consecutive Michael-Claisen process for CDD synthesis. The reaction exhibited remarkable regioselectivity in Michael addition followed by Claisen cyclization. In this process high substrate selectivity was observed for CDD synthesis following consecutive double-Michael-Claisen and Michael-Claisen cyclization. Georg Thieme Verlag Stuttgart · New York.

Pyrazolopyridine cycloalkanones and process for their preparation

Novel tetrahydropyrazolo-[3,4-b]quinolinones, cyclopenta[b]pyrazolo-[4,3-e]pyridinones and cyclohepta[b]-pyrazolo[4,3-e]pyridinones, useful as anxiolytics having reduced side effects, are disclosed, including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.